
Trump Calls on Congress to Preserve Full-Spectrum CBD Access
President urges lawmakers to prevent November recriminalization while backing restrictions on high-risk hemp products
President Donald Trump has called on Congress to amend federal law before November to prevent the recriminalization of full-spectrum CBD products, while simultaneously pushing for new restrictions on hemp-derived products that pose health risks.
The president's statement comes as a statutory deadline threatens to upend the legal status of full-spectrum CBD—products that contain trace amounts of THC alongside CBD and other hemp compounds. "I am calling on Congress to update the Law to ensure that Americans can continue to access the full-spectrum CBD products they have come to rely on," Trump said.
The urgency stems from provisions in existing hemp legislation that could automatically recriminalize certain CBD products in November. Full-spectrum CBD has become a cornerstone of the legal hemp industry since the 2018 Farm Bill federally legalized hemp and its derivatives. Unlike CBD isolate, full-spectrum products contain the plant's complete range of cannabinoids, terpenes, and other compounds—including up to 0.3% THC.
The Balancing Act
Trump's position reflects a dual approach: preserving consumer access to established CBD products while addressing concerns about newer, more potent hemp-derived intoxicants. The hemp market has exploded since 2018, spawning products that range from wellness-focused CBD tinctures to THC-adjacent compounds like delta-8 and delta-10.
Industry groups have long warned about this potential regulatory cliff. The Hemp Industries Association estimates that full-spectrum CBD products represent a $2.8 billion segment of the broader hemp market. A sudden recriminalization would devastate thousands of small businesses and cut off access for millions of consumers who use these products for pain management, anxiety, and sleep issues.
But the president's statement also acknowledges growing bipartisan concern about unregulated hemp-derived intoxicants flooding convenience stores and gas stations. Products marketed as "legal highs" have raised alarms among parents, educators, and some lawmakers who argue the 2018 Farm Bill created loopholes never intended by Congress.
Industry Response
The CBD industry has been bracing for regulatory changes. Jonathan Miller, general counsel for the U.S. Hemp Roundtable, has previously stated that clarity from Congress is essential. "The industry needs clear rules that protect consumers while preserving the legitimate hemp market," he said in recent testimony.
Manufacturers of full-spectrum CBD products argue their offerings are fundamentally different from synthetic or semi-synthetic intoxicants. These traditional hemp extracts have been in commerce for years with relatively few safety concerns, they contend. The products typically contain naturally occurring ratios of cannabinoids as they appear in the hemp plant.
Yet defining which products deserve protection and which require restriction won't be simple. The hemp market now includes everything from grandmother-friendly CBD gummies to vape cartridges that deliver experiences similar to marijuana. Congressional action would need to draw clear lines—something lawmakers have struggled to do since hemp legalization.
What's Next
Congress faces a tight timeline if it wants to act before the November deadline. Both chambers would need to draft, debate, and pass legislation that threads the needle between consumer access and public health protection. That's no small task in an election year, particularly for an issue that divides both parties internally.
Some lawmakers have already introduced bills aimed at reining in intoxicating hemp products. Senator Ron Wyden and Representative Earl Blumenauer, both Oregon Democrats, have proposed frameworks that would preserve traditional CBD while creating new restrictions. Republican representatives have also floated similar concepts, though details vary widely.
The White House statement adds presidential pressure to what has been largely a legislative debate. Whether Trump's call to action will accelerate congressional movement remains uncertain. But with billions in commerce and millions of consumers at stake, the hemp industry is watching closely.
The outcome will likely shape the hemp market for years to come—determining not just which products remain legal, but how strictly the federal government regulates an industry it only recently allowed to exist.
This article is based on original reporting by www.marijuanamoment.net.
Original Source
This article is based on reporting from Marijuana Moment.
Read the original articleOriginal title: "Trump Pushes Congress To Keep Full-Spectrum CBD Legal While Restricting Hemp Products That Pose ‘Health Risks’"
Related Topics
Related Stories
LegislationTrump Administration Moves Cannabis to Schedule III in Partial Win
The Trump administration rescheduled cannabis to Schedule III, providing tax relief to licensed operators but stopping short of full legalization. The move leaves banking restrictions and federal prohibition intact.
LegislationTrump Endorses Medical Cannabis as 'Best Alternative' for Patients
President Trump called medical marijuana "the best of all the alternatives" for patients Thursday, hours after DOJ advanced its cannabis rescheduling proposal from Schedule I to Schedule III.
LegislationIRS to Issue Tax Guidance as Schedule III Takes Effect for Medical Cannabis
Treasury officials will issue new tax guidance following the Trump administration's order moving state-licensed medical marijuana to Schedule III, potentially ending 280E tax penalties for qualifying businesses.
More from Alex Morgan
View all articles
Trump Administration Moves Cannabis to Schedule III in Partial Win

Cannabis Operators Pivot Strategy as Schedule III Decision Looms

Trump Endorses Medical Cannabis as 'Best Alternative' for Patients

